Citations

Showing 10 of 108081 citations.

Abstract 91: Alternatives to ADM: Utilization of a Gore DualMesh Sling as a Cost Conscious Adjunct for Breast Reconstruction
Grow, Jacob N., Butterworth, James , Petty, Paul M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 28, 2017 | Volume: 5 | Issue: 4S | Pages: 68-69

10.1097/01.gox.0000516611.02256.54 Get It

Using Biomarkers to Guide Heart Failure Therapy
Jaffe, Allan S. , Jaffe, Allan S. , Januzzi, James Louis

Mayo Clinic

Clinical Chemistry | April 28, 2017 | Volume: 63 | Issue: 5 | Pages: 954-957

10.1373/clinchem.2016.266106 | PMID 28280051 Get It

Long-term outcomes of cemented versus cementless humeral components in arthroplasty of the shoulder
Werthel, J-D., Lonjon, G. , Cofield, Robert H. , Sperling, John W. , Elhassan, Bassem T. , Jo, Suenghwan

Mayo Clinic

The Bone & Joint Journal | April 28, 2017 | Volume: 99-B | Issue: 5 | Pages: 666-673

10.1302/0301-620x.99b5.bjj-2016-0910.r1 | PMID 28455477 Get It

Aims In the initial development of total shoulder arthroplasty (TSA), the humeral component was usually fixed with cement. Cementless components were subsequently introduced. The aim of this study was to compare the long-term outcome of cemented and cementless humeral components in arthroplasty of the shoulder. Patients and Methods All patients who underwent primary arthroplasty of the shoulder at our institution between 1970 and 2012 were included in the study. There were 4636 patients with 1167 cemented humeral components and 3469 cementless components. Patients with the two types of fixation were matched for nine different covariates using a propensity score analysis. A total of 551 well-balanced pairs of patients with cemented and cementless components were available after matching for comparison of the outcomes. The clinical outcomes which were analysed included loosening of the humeral component determined at revision surgery, periprosthetic fractures, post-operative infection and operating time. Results The overall five-, ten-, 15- and 20-year rates of survival were 98.9%, 97.2%, 95.5%, and 94.4%, respectively. Survival without loosening at 20 years was 98% for cemented components and 92.4% for cementless components. After propensity score matching including fixation as determined by the design of the component, humeral loosening was also found to be significantly higher in the cementless group. Survival without humeral loosening at 20 years was 98.7% for cemented components and 91.0% for cementless components. There was no significant difference in the risk of intra- or post-operative fracture. The rate of survival without deep infection and the mean operating time were significantly higher in the cemented group. Conclusion Both types of fixation give rates of long-term survival of > 90%. Cemented components have better rates of survival without loosening but this should be weighed against increased operating time and the risk of bony destruction of the proximal humerus at the time of revision of a cemented humeral component. Cite this article: Bone Joint J 2017;99-B:666–73.
Integrative medicine in cancer survivors
Viscuse, Paul V. , Price, Katharine A., Millstine, Denise , Bhagra, Anjali , Bauer, Brent A. , Ruddy, Kathryn J.

Mayo Clinic

Current Opinion in Oncology | April 28, 2017 | Volume: 29 | Issue: 4 | Pages: 235-242

10.1097/cco.0000000000000376 | PMID 28459738 Get It

Purpose of review Due to medical advances and an aging population, the number of cancer survivors continues to rise. Survivors often experience late and long-term sequelae of cancer and its treatment (e.g., fatigue, pain, fear of recurrence, and stress). As a result, some patients have utilized or expressed interest in integrative medicine (IM) modalities for prevention of recurrence, optimizing health, enhancing quality of life, and managing symptoms. The purpose of this review is to focus on research published during the past year that informs our understanding of the utility of IM for cancer survivors. Recent findings Physical activity, diet, dietary supplements, mind–body modalities, acupuncture, and massage therapy all may play a role in the management of the physical (e.g., fatigue and pain) and emotional (e.g., anxiety and fear) issues faced by cancer survivors. Summary IM therapies are appealing to and utilized by many cancer survivors and may reduce symptom burden. Clinicians who provide cancer survivorship care may improve patient care by understanding the evidence for and against their use.
Contemporary failure aetiologies of the primary, posterior-stabilised total knee arthroplasty
Kobic, Ajdin, Taunton, Michael J. , Hanssen, Arlen D. , Abdel, Matthew P. , Ledford, Cameron K. , Taunton, Michael J

Mayo Clinic

The Bone & Joint Journal | April 28, 2017 | Volume: 99-B | Issue: 5 | Pages: 647-652

10.1302/0301-620x.99b5.bjj-2016-0617.r3 | PMID 28455474 Get It

Aims The number of revision total knee arthroplasties (TKA) that are performed is expected to increase. However, previous reports of the causes of failure after TKA are limited in that they report the causes at specific institutions, which are often dependent on referral patterns. Our aim was to report the most common indications for re-operations and revisions in a large series of posterior-stabilised TKAs undertaken at a single institution, excluding referrals from elsewhere, which may bias the causes of failure. Patients and Methods A total of 5098 TKAs which were undertaken between 2000 and 2012 were included in the study. Re-operations, revisions with modular component exchange, and revisions with non-modular component replacement or removal were identified from the medical records. The mean follow-up was five years (two to 12). Results The Kaplan-Meier ten-year survival without a re-operation, modular component revision and non-modular component revision was 95.7%, 99.3% and 95.3%, respectively. The most common indications for a re-operation were: post-operative stiffness (58%), delayed wound healing (21%), and patellar clunk (11%). The indications for isolated modular component revision were acute periprosthetic joint infection (PJI) (64%) and instability (36%). The most common indications for non-modular component revision were chronic PJI (52%), aseptic loosening (17%), periprosthetic fracture (10%), and instability (10%). Conclusion Post-operative stiffness remains the most common indication for re-operation after TKA. Infection is the most common indication for modular and non-modular component revision. Aseptic loosening was not an uncommon cause of failure, however, it was much less common than in national registry and non-registry data. Focusing on posterior-stabilised TKAs initially performed at our institution allowed for an accurate assessment of the causes of failure in a contemporary specialty practice. Cite this article: Bone Joint J 2017;99-B:647–52.
Beta‐blockers in patients with advanced cirrhosis: Red light, green light, yellow light…
Peeraphatdit, Thoetchai , Kamath, Patrick S. , Shah, Vijay H. , Peeraphatdit, Thoetchai Bee

Mayo Clinic

Liver Transplantation | April 28, 2017 | Volume: 23 | Issue: 6 | Pages: 725-726

10.1002/lt.24780 | PMID 28452116 Get It

Treatments to Prevent Bone Loss in Functional Hypothalamic Amenorrhea: A Systematic Review and Meta-Analysis
Altayar, Osama , Nofal, Alaa Al , Leon, Barbara Gisella Carranza, Murad, M. Hassan , Al Nofal, Alaa, Prokop, Larry J. , Wang, Zhen , Murad, M Hassan , Al Nofal, Alaa , Altayar, Osama

Mayo Clinic

Journal of the Endocrine Society | April 27, 2017 | Volume: 1 | Issue: 5 | Pages: 500-511

10.1210/js.2017-00102 | PMID 29264505 Get It

Review of: Atlas of Gross Neuropathology: A Practical Approach
Reichard, R. Ross

Mayo Clinic

Journal of Forensic Sciences | April 27, 2017 | Volume: 62 | Issue: 3 | Pages: 834-834

10.1111/1556-4029.13423 Get It

A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)
Perentesis, John P. , Liu, Xiaowei , Kudgus, Rachel A. , Fox, Elizabeth , Blaney, Susan M. , Weigel, Brenda J. , Reid, Joel M. , Geller, James I. , Minard, Charles G.

Mayo Clinic

Pediatric Blood & Cancer | April 27, 2017 | Volume: 64 | Issue: 11 | Pages: No page available

10.1002/pbc.26565 | PMID 28449393 Get It

AbstractBackgroundThe c‐Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c‐Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors.MethodsOral tivantinib capsules were administered twice daily with food, continuously in 28‐day cycles. Dose levels 170, 200, and 240 mg/m2/dose were evaluated using a rolling‐six design (Part A). In Part B, subjects received tivantinib powder sprinkled on food at the recommended phase 2 dose (RP2D) from Part A. PK, CYP2C19 genotyping, and baseline tumor tissue c‐Met expression were analyzed.ResultsThirty‐six patients were enrolled: 20 in Part A, 6 in a PK expansion cohort, and 10 in Part B. Fifteen patients had primary central nervous system tumors and 21 had solid tumors. In Part A, there were no dose‐limiting toxicities. One grade 4 intracranial hemorrhage occurred in a patient with a progressive brain tumor in the expanded PK cohort (240 mg/m2). PK analysis showed marked interpatient variability (20‐fold) in the Cmax and AUC0‐8h across all dose levels. Sprinkling tivantinib powder over food did not alter exposure. Membranous and total c‐Met expression was moderate (2), low (4), or not detected (26). Two patients had stable disease as the best response.ConclusionsThe RP2D of tivantinib given with food in children with refractory solid tumors is 240 mg/m2/dose. PK of tivantinib in children demonstrated high variability. Objective responses were not observed in this phase 1 trial.
A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups
Yin, Jun , Qin, Rui , Erlichman, Charles , Shi, Qian , Sargent, Daniel J. , Shi, Qian

Mayo Clinic

Journal of Biopharmaceutical Statistics | April 27, 2017 | Volume: 28 | Issue: 3 | Pages: 451-462

10.1080/10543406.2017.1321007 | PMID 28448747 Get It